You are here: Industry Insights > CDF

News List

NHS England unveils new Innovative Medicine Fund pharmatimes
July 22, 2021
NHS England has unveiled its new Innovative Medicines Fund (IMF), to ensure patients have early access to ‘potentially life-saving’ new treatments.
NICE approves Keytruda combination therapy for NSCLC through CDF pharmaceutical-technology
August 09, 2019
The UK’s healthcare regulator the National Institute of Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) combined with two chemotherapy drugs ...
NHS U-turns on Afinitor for TSC-related epilepsy pharmaphorum
December 25, 2018
NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019.
NHS funds BMS’ Opdivo to prevent skin cancer returning pharmaphorum
December 03, 2018
NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year to reject the drug in this indication.
Merck impresses NICE with Keytruda data—and discounts—cueing up a CDF switch fiercepharma
June 11, 2018
England's cost watchdogs have recommended moving Merck's Keytruda off the Cancer Drugs Fund and making it available for routine use. (Merck)
Roche’s Tecentriq available via CDF pharmatimes
December 08, 2017
Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for certain patients with metastatic urothelial carcinoma.
NICE expands Bayer's Stivarga prospects with move from CDF fiercepharma
October 13, 2017
Since the National Institute for Health and Care Excellence took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their oncology meds get the boot. Not Bayer.
3 in 4 of CDF treatments now approved on NHS pharmaceutical-technology
August 16, 2017
75% of cancer treatments previously accessible through the Cancer Drugs Fund (CDF) are now available for patients on the NHS England.
NICE approves three quarters of the Cancer Drugs Fund europeanpharmaceuticalreview
August 15, 2017
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF…
Pancreatic cancer patients in England get CDF access to Abraxane pharmatimes
August 07, 2017
Patients with pancreatic cancer living in England can from today potentially get access to a new treatment option after funding for Celgene’s Abraxane was approved for NHS use.

Previous page 1 2 Next page